The firm lowered the price target to $10 from $11 for the entrepreneurial pharmaceutical company.
Cantor Fitzgerald said it lowered the company's ratings because of a valuation call, as the company will likely spend more on research and development in the new year.
Must Read: Warren Buffett's 25 Favorite Stocks
"We believe that sentiment may turn even more negative if risky clinical programs fail and there is heightened anticipation of additional financing needs," said Cantor Fitzgerald specialty pharmaceutical analyst Irina Rivkind Koffler.
Shares of Ironwood Pharmaceuticals are up 3.97% to $13.09 in mid-day trading on Thursday.
Separately, TheStreet Ratings team rates IRONWOOD PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate IRONWOOD PHARMACEUTICALS INC (IRWD) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been very high debt management risk by most measures."
Highlights from the analysis by TheStreet Ratings Team goes as follows: